Andrés Navarro Ruiz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/961415/publications.pdf

Version: 2024-02-01

37 papers 582 citations

687363 13 h-index 23 g-index

44 all docs 44 docs citations

times ranked

44

578 citing authors

#	Article	IF	Citations
1	Effect of Early Peripheral Parenteral Nutrition Support in an Enhanced Recovery Program for Colorectal Cancer Surgery: A Randomized Open Trial. Journal of Clinical Medicine, 2021, 10, 3647.	2.4	9
2	Adequacy of Parenteral Nutrition in Preterm Infants According to Current Recommendations: A Study in A Spanish Hospital. International Journal of Environmental Research and Public Health, 2020, 17, 2131.	2.6	5
3	Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. Pharmaceutics, 2020, 12, 316.	4.5	17
4	Consensus to identify the dangerous drugs risks in hospital pharmacy services. Farmacia Hospitalaria, 2020, 44, 51-61.	0.6	2
5	Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System. Pharmaceutics, 2019, 11, 567.	4.5	27
6	Adaptation of a deprescription intervention to the medication management of older people living in long-term care facilities. Expert Opinion on Drug Safety, 2019, 18, 1091-1098.	2.4	5
7	Impact on intestinal permeability of pediatric hyperosmolar formulations after dilution: Studies with rat perfusion method. International Journal of Pharmaceutics, 2019, 557, 154-161.	5.2	6
8	Desarrollo de la gestión del proceso general de la manipulación de los medicamentos peligrosos en las unidades de hospitalización a domicilio. Hospital A Domicilio, 2019, 3, 9.	0.1	2
9	Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. European Journal of Hospital Pharmacy, 2018, 25, 200-203.	1.1	1
10	Development and validation of a guide for the continuity of care in perioperative medication management. Journal of Orthopaedics and Traumatology, 2018, 19, 4.	2.3	1
11	Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. British Journal of Clinical Pharmacology, 2018, 84, 2231-2241.	2.4	18
12	Relaci \tilde{A}^3 n entre el polimorfismo rs 1414334 C/G del gen HTR2C y tabaquismo en pacientes tratados con antipsic \tilde{A}^3 ticos at \tilde{A} picos. Revista De Psicologia De La Salud, 2018, 30, 123.	0.5	1
13	Development and Validation of a Rapid UV-HPLC Method for the Determination of Anidulafungin in Perfusion Solution. Current Pharmaceutical Analysis, 2017, 13, 314-320.	0.6	1
14	Pharmacokinetic monitoring of chronic treatment with digoxin from Primary Health Care. Farmacia Hospitalaria, 2017, 41, 527-532.	0.6	4
15	Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review. Farmacia Hospitalaria, 2017, 41, 625-629.	0.6	2
16	Prevalence of Potential Drug-Drug Interactions in Hospitalized Surgical Patients. Journal of Pharmacy and Pharmacology, 2016, 4, .	0.0	3
17	Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics. PeerJ, 2016, 4, e2163.	2.0	7
18	Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 71-79.	1.4	2

#	Article	IF	Citations
19	Treatment of hyponatremia induced by the syndrome of Inappropriate antidiuretic hormone secretion: a multidisciplinary spanish algorithm. Nefrologia, 2014, 34, 439-50.	0.4	20
20	Filgrastim use in the emergency department of a Spanish general hospital. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 492-496.	0.6	0
21	Adverse Cutaneous Reactions Induced by TNF-α Antagonist Therapy. Southern Medical Journal, 2009, 102, 1133-1140.	0.7	43
22	Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. Journal of Antimicrobial Chemotherapy, 2008, 62, 879-888.	3.0	88
23	Unrecognized Delayed Toxic Lithium Peak Concentration in an Acute Poisoning with Sustained Release Lithium Product. Southern Medical Journal, 2007, 100, 321-323.	0.7	11
24	Successful Treatment of Severe Gastrointestinal Bleeding Secondary to Crohn Disease with Recombinant Factor VIIa. Southern Medical Journal, 2007, 100, 601-604.	0.7	11
25	Extracorporeal Removal of Vancomycin by Plasmapheresis. Annals of Pharmacotherapy, 2006, 40, 2279-2280.	1.9	9
26	Ciprofloxacin, but not Levofloxacin, Affects Cyclosporine Blood Levels in a Patient with Pure Red Blood Cell Aplasia. American Journal of the Medical Sciences, 2005, 330, 144-146.	1.1	10
27	Use of Recombinant Factor VIIa for Life-threatening Bleeding in a Patient With Severe Necrotizing Pancreatitis. Pancreas, 2005, 31, 292-294.	1.1	1
28	Recombinant Factor VIIa is an Effective Therapy for Abdominal Surgery and Severe Thrombocytopenia: A Case Report. International Journal of Hematology, 2005, 81, 75-76.	1.6	10
29	Pure Red Cell Aplasia Associated with Dapsone Therapy. Annals of Pharmacotherapy, 2005, 39, 1137-1138.	1.9	11
30	Acute Seizures Due to a Probable Interaction between Valproic Acid and Meropenem. Annals of Pharmacotherapy, 2005, 39, 533-537.	1.9	71
31	Optic Neuritis with Concurrent Etanercept and Isoniazid Therapy. Annals of Pharmacotherapy, 2005, 39, 2131-2135.	1.9	38
32	Acenocoumarol-Induced Henoch-SchĶnlein Purpura. Annals of Pharmacotherapy, 2004, 38, 261-264.	1.9	18
33	Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: A Cost–Utility Analysis in Spain. Value in Health, 2004, 7, 52-60.	0.3	34
34	Photo-Induced Stevens–Johnson Syndrome Due to Sulfasalazine Therapy. Annals of Pharmacotherapy, 2003, 37, 1241-1243.	1.9	15
35	Probable Interaction between Citalopram and Acenocoumarol. Annals of Pharmacotherapy, 2002, 36, 345-345.	1.9	20
36	Multiple Fixed-Drug Eruption and Diarrhea with Ticlopidine. Annals of Pharmacotherapy, 2002, 36, 344-345.	1.9	11

#	Article	IF	CITATIONS
37	Midazolam and haloperidol for palliative sedation: physicochemical stability and compatibility of parenteral admixtures. Brazilian Journal of Pharmaceutical Sciences, 0, 55, .	1.2	O